What Massive Bio does

Massive Bio, Inc. is a privately held, Delaware-incorporated AI company headquartered in Boca Raton, Florida, founded in 2015. It operates SYNERGY-AI, an oncology-focused clinical trial matching platform that processes more than 500 medical data elements per patient across 19,000+ active oncology and hematology trials in 17 markets. The platform serves three primary customer segments — cancer patients and caregivers (free, self-serve access via multilingual website and iOS/Android apps), referring oncologists and clinical staff (TrialRelay enrollment orchestration), and 45 enterprise pharma and CRO customers (TrialRelay, NexusPulse commercial/medical intelligence, and Real World Data products). A network of 400+ patient advocacy organizations and 130+ strategic partners (including the American Cancer Society, TOUCH BBCA, Flatiron Health, Foundation Medicine, OpenAI, Optellum, Oracle Cerner, and BeeKeeperAI) feeds consented patient flow into the matching pipeline.

The company's underlying technology is a neuro-symbolic, three-agent AI architecture grounded in an oncology-specific knowledge graph, which Massive Bio bundles as the Reticulum Nexus operating system alongside discrete modules such as Patient Connect, TrialRelay (powered by TrialRouter AI), NexusPulse, DrArturo AI, Phoebe AI, and Sentinel Agents. Performance is backed by a peer-reviewed prospective study in ESMO Real World Data and Digital Oncology covering 3,804 cancer patients and 157,000+ clinical documents, which demonstrated 4x faster trial matching than conventional methods, and by a >40% reduction in signal-to-action time from NexusPulse deployments. Massive Bio maintains a broad regulatory and compliance posture spanning HIPAA, GDPR, PIPEDA, LGPD, SOC 2, DiMe Seal 2026, CMS Medicare App Library listing, OHRP FWA (FWA00030601), and EMA Clinical Trial Regulation registration.

The business model is multi-stream: sponsor-supported managed services (pharma/CRO-funded concierge, navigation, and last-mile coordination), enterprise SaaS contracts for patient identification and enrollment acceleration, and licensing of de-identified real-world data and analytics to patient assistance programs, labs, and pharmaceutical manufacturers. The patient-facing service is free, so monetization runs entirely through enterprise and sponsor channels. To date, Massive Bio has raised approximately $23.3M in cumulative disclosed funding across multiple rounds through a $16.5M Series B led by Revo Capital in December 2022, and the company remains founder-led by CEO Selin Kurnaz, PhD, Chief Medical AI Officer Arturo Loaiza-Bonilla, MD, MSEd, FACP, and CTO/COO Çağatay M. Çulcuoğlu.

Name

Massive Bio

Legal name

Massive Bio Inc.

Website

https://massivebio.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Massive Bio operates an AI-powered oncology clinical trial matching platform serving cancer patients, oncologists, and 45 pharma/CRO sponsors across 17 markets, anchored by its SYNERGY-AI engine and Reticulum Nexus multi-agent ecosystem.

Ownership category

akta.pro rank

Product category

Oncology Clinical Trial Matching Platform

NAICS

Computer Systems Design and Related Services (54151), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Prepackaged Software (7372), Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials) (HLAAANAI)

akta.pro secondary industries

Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF), Clinical Decision Support & Workflow Integration (EHR/oncology systems) (HLAAANAE), Clinical Trial Site Operations & Study Coordination (HLAGACAE)

Keywords

• Clinical trial matching
• Oncology patient recruitment
• AI clinical trials
• Real-world data analytics
• Patient navigation services

Headquarters

HQ city

Boca Raton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D

Revenue model

1. Sponsor-Supported Services: Clinical trial sponsors (pharmaceutical or biotechnology companies) fund concierge, navigation, and last-mile coordination services via payments made directly to Massive Bio. Funding does not affect patient rights, cost of care, or eligibility, and is disclosed transparently in patient-facing consents. Identifiable patient data is not shared with sponsors — only de-identified aggregate study metrics.
2. Enterprise SaaS — Pharma / CRO Patient Identification and Trial Enrollment: B2B contracts with 45 pharma and CRO customers (per company) for patient identification, trial enrollment acceleration, site identification, and Real World Data analytics, including TrialRelay™ enrollment orchestration and NexusPulse™ commercial/medical intelligence.
3. De-Identified Real-World Data and Analytics Licensing: Massive Bio uses Non-PII to consult other users and may share, lease, or sell de-identified data and analysis to patient assistance programs, clinical laboratories, cancer screening providers, pharmaceutical manufacturers, and oncologists for improvement of professional services and to educate the public.
4. Patient-Facing Service (Free to Patients): Cancer patients and caregivers receive clinical trial matching, second-opinion reports, and patient navigation at no cost; revenue is captured indirectly through sponsor and enterprise contracts rather than direct patient fees.

Pricing tiers

Go-to-market motion5 records

Distribution channels7 records

Marketing channels9 records

Core offering

Massive Bio operates an AI-powered oncology clinical trial matching platform (SYNERGY-AI) wrapped in the Reticulum Nexus multi-agent operating system, processing 500+ medical data elements per patient against 19,000+ active oncology and hematology trials across 17 markets and 11 languages to deliver physician-reviewed trial reports within 24 hours. It sells TrialRelay physician-facing enrollment orchestration, NexusPulse real-time AI commercial/medical intelligence, and de-identified Real World Data products to pharmaceutical companies, CROs, health systems, and patient advocacy organizations, while offering free clinical trial matching, navigation, and educational content to cancer patients and caregivers.

Product overview

Massive Bio offers a single unified AI-powered oncology intelligence platform anchored by its flagship SYNERGY-AI™ clinical trial matching engine, wrapped in the next-generation Reticulum Nexus™ multi-agent operating system that orchestrates the full oncology patient journey. The Reticulum Nexus™ suite integrates discrete modules — Patient Connect™ (patient-facing navigation), TrialRelay™ (physician-facing enrollment orchestration) powered by TrialRouter™ AI, NexusPulse™ (real-time AI signal engine for oncology markets), NexusPulse™ Intelligent Calculators, and AI agents Sentinel Agents™, DrArturo AI™, and Phoebe AI™ — into one real-time system. The platform's neuro-symbolic, three-agent AI architecture is grounded in an oncology-specific knowledge graph and validated across 3,804 patients with four-times-faster matching than conventional methods. Supporting products include mobile apps (Synergy-AI Clinical Trial Finder and Cancer Quiz), an Oracle Cerner EHR-integrated app, complementary services (Clinical Trial Matching, Virtual Tumor Board, Drug Utilization Optimizer (DUO), Real World Data), and the Little Tales for Massive Heroes pediatric storybook.

Differentiator

Problem solved

Functional benefit

Brands

• SYNERGY-AI: Massive Bio's AI-powered clinical trial matching platform used to match cancer patients with oncology and hematology clinical trials.
• Reticulum Nexus
• TrialRelay
• NexusPulse
• Patient Connect
• TrialRouter
• DrArturo AI
• Phoebe AI
• Sentinel Agents

Products and services

• SYNERGY-AI Clinical Trial Matching Platform AI-powered clinical trial matching platform that processes 500+ medical data elements per patient against 19,000+ active oncology and hematology trials, delivering personalized physician-reviewed trial reports within 24 hours to cancer patients, oncologists, and sponsors across 17 markets. Validated across 3,804 cancer patients and 157,000+ clinical documents.
• Reticulum Nexus Product Suite AI-powered multi-agent oncology intelligence ecosystem and operating system for oncology access. Orchestrates patient engagement, medical records, eligibility interpretation, clinical trial pre-screening, physician referral orchestration, biomarker intelligence, site activation, and patient navigation into a single real-time AI-enabled operating layer for patients, physicians, sponsors, and CROs.
• TrialRelay Physician-facing AI-powered enrollment orchestration platform powered by TrialRouter AI that eliminates 'referral black holes' by providing warm handoffs, continuous visibility, and closed-loop accountability for oncology patient referrals across health systems and external institutions. Sold to oncologists, health systems, and pharma/CRO sponsors.
• NexusPulse Real-time AI signal engine for oncology markets that transforms consented real-world clinical and biomarker data into actionable commercial, medical, and market access intelligence for pharma and CRO customers. Built within the Reticulum Nexus ecosystem.
• Patient Connect Patient-facing trial navigation tool that empowers cancer patients and caregivers to manage and navigate their clinical trial journey anytime, anywhere, all in one place. Free to patients; bundled within the Reticulum Nexus ecosystem.
• Virtual Tumor Board Online service providing remote access to bioinformatics and molecular expertise to support patient presentations at tumor boards for oncologists and care teams.
• Drug Utilization Optimizer (DUO)

Quantifiable outcome

• 4x faster AI-driven trial matching vs. conventional methods, validated across 3,804 cancer patients and 157,000+ clinical documents (peer-reviewed in ESMO Real World Data and Digital Oncology)
• +6 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability15 records

Feature10 records

Partnerships

Eleven partnerships are on record, tiered flagship strategic partner, core technology partner, core strategic partner, flagship technology partner and strategic partner.

• Optellumflagship strategic partnerStrategic or Co-development Partner · 3 June 2026Strategic collaboration announced June 2026 to connect AI-powered lung cancer detection with clinical trial matching for early-stage NSCLC patients. Optellum's FDA-cleared Lung Cancer Prediction (LCP) AI identifies high-risk patients from CT imaging; de-identified data is processed by Massive Bio's platform to match them with geographically accessible NSCLC clinical trials. Targets the gap where most high-risk patients never reach trials despite early detection raising 5-year survival from 9% to 64%.
• BeeKeeperAIcore technology partnerTechnology or Integration · 30 May 2026Collaboration enabling privacy-preserving AI-powered clinical trial matching in oncology through encrypted computing, allowing AI models to run on sensitive patient data without exposing it.
• TOUCH, The Black Breast Cancer Alliance (BBCA)core strategic partnerGTM or Marketing Partner · 29 May 2026Embeds Massive Bio's SYNERGY-AI clinical trial matching technology into TOUCH BBCA's digital platform to provide free personalized trial options for Black breast cancer patients and other underrepresented communities. TOUCH BBCA had previously facilitated over 35,000 patient searches before integration; part of Massive Bio's broader strategy to build trusted patient-facing networks that improve equitable access to clinical research.
• Navigating Trialscore strategic partnerGTM or Marketing Partner · 29 May 2026Diversity-focused patient navigation platform launched February 2026; its navigators follow up with patients matched via SYNERGY-AI to guide them through the clinical trial enrollment process. Provides the navigator layer complementing Massive Bio's AI matching for underrepresented communities.
• Just Worldwidecore strategic partnerStrategic or Co-development Partner · 14 May 2026Strategic partnership combining Just Worldwide's multicultural patient engagement infrastructure with Massive Bio's SYNERGY-AI platform. Just Worldwide leverages fieldwork across North America, Europe, and Asia to raise awareness, onboard patients, and collect medical records that flow through Massive Bio's matching infrastructure. Aims to address clinical trial underenrollment by routing patients through trusted community networks.
• OpenAIflagship technology partnerTechnology or Integration · 29 April 2026Collaboration to broaden clinical trial access through AI-powered parameterization and pre-screening using OpenAI models. Supports Massive Bio's expansion of global access to clinical trials via integration with OpenAI's generative AI capabilities.
• American Cancer Society (ACS)flagship strategic partnerStrategic or Co-development Partner · 18 November 2025Co-developed and powers the ACS ACTS nationwide clinical trial matching program using SYNERGY-AI. Pilot launched Feb 24, 2025 in the Northeast, delivering 900+ trial opportunities and engaging 1,000+ individuals before national expansion to all 50 U.S. states and territories in November 2025. Reduces geographic, financial, and cultural barriers to cancer clinical trial participation.
• Flatiron Healthcore strategic partnerStrategic or Co-development Partner · 7 April 2025Strategic partnership announced April 2025 to expand patient identification capabilities and accelerate clinical trial enrollment across the U.S. Leverages Massive Bio's U.S.-based patient database to identify patients near participating Flatiron research sites who may benefit from trial enrollment, reducing disparities in access and improving outcomes for cancer patients.
• Foundation Medicinecore strategic partnerStrategic or Co-development Partner · 13 September 2024Strategic partnership to optimize clinical trial recruitment and expand access to precision cancer care. Combines Massive Bio's digital platform with Foundation Medicine's genomic expertise to increase oncology clinical trial participation through AI-driven patient matching.
• Oracle Cernercore technology partnerTechnology or IntegrationNative Oracle Cerner App launch to simplify patient records ingestion and speed up clinical trial matching by integrating directly with Cerner EHR systems.
• Prognos Healthstrategic partnerStrategic or Co-development PartnerStrategic partnership announced to expand oncology access by combining Prognos Health's real-world data capabilities with Massive Bio's SYNERGY-AI matching platform.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Deep 6 AI: AI-driven clinical trial patient matching and site feasibility platform. Directly comparable to Massive Bio's SYNERGY-AI: both sell AI-based patient identification and trial recruitment software to pharma, CROs, and health systems.
• Mendel: AI platform for clinical trial recruitment, real-world data extraction, and patient cohort identification from unstructured medical records. Closely comparable to Massive Bio's oncology trial matching and RWD analytics offerings.
• Trial Library: Clinical trial matching and recruitment platform that connects patients and physicians to relevant oncology trials. Direct peer to Massive Bio's patient-facing matching engine, with overlapping pharma/sponsor GTM.
• ConcertAI: Oncology-focused real-world data and AI platform for trial design, patient identification, and evidence generation. Directly comparable to Massive Bio's NexusPulse and RWD products for oncology sponsors.
• Flatiron Health: Oncology-specific real-world data and EHR platform (Roche-owned) used by sponsors and providers for trial enrollment and evidence. Massive Bio has a formal partnership with Flatiron and competes for the same pharma/CRO RWD and patient identification budgets.
• Foundation Medicine: Genomic profiling company (Roche-owned) that powers precision oncology trial enrollment and companion diagnostics. Massive Bio has an active partnership with Foundation Medicine and competes for precision oncology enrollment budgets.

Broad incumbents

• Tempus: Large-scale precision medicine platform combining genomic profiling, AI, and real-world data for oncology and broader indications. Overlaps with Massive Bio on AI-driven trial matching, biomarker intelligence, and pharma RWD, but operates at much broader scale.
• IQVIA: Global CRO and life sciences technology company offering E360, patient recruitment, real-world evidence, and AI trial design. Massive Bio competes with IQVIA's AI recruitment and RWD products for the same oncology sponsor wallet.

Emerging players

• Syapse: Precision oncology real-world evidence and trial-matching platform serving health systems and life sciences companies. Comparable to Massive Bio on community oncology RWD and pharma RWE partnerships.

Others

• BeeKeeperAI: Privacy-preserving / confidential computing AI platform for healthcare and life sciences. Massive Bio is a strategic BeeKeeperAI partner; relevant adjacent technology provider rather than a direct trial-matching competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights8 records

Customer concentration

• Xx.com/massivebio
• Facebookfacebook.com/massivebio
• LinkedInlinkedin.com/company/massive-bio

Compliance18 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds7 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Massive Bio